Key Takeaways Ozempic and Wegovy made up 66% of NVO sales in 9M 2025, making their Q4 performance central to results.Novo Nordisk faces slower U.S. momentum as compounded alternatives and intense rivalry weigh on Wegovy uptake.Beyond GLP-1s, Rybelsus, insulin and Rare Disease products likely supported NVO's overall revenues in Q4.Novo Nordisk (NVO) is a dominant player in the cardiometabolic space, mainly due to the encouraging uptake of its blockbuster semaglutide-based (GLP-1) drugs — Ozempic (for type II ...